EUCAST technical note on Amphotericin B

Clin Microbiol Infect. 2011 Dec;17(12):E27-9. doi: 10.1111/j.1469-0691.2011.03644.x. Epub 2011 Oct 19.

Abstract

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B for Candida spp. This Technical Note is based on the EUCAST amphotericin B rationale document (available on the EUCAST website: http://www.eucast.org). Species-specific breakpoints for C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis are S: MIC ≤1 mg/L, R: MIC > 1 mg/L. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-ff values and clinical experience. Breakpoints will be reviewed regularly.

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / pharmacokinetics
  • Amphotericin B / pharmacology*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Candida / isolation & purification
  • Candidiasis / drug therapy
  • Candidiasis / microbiology*
  • Drug Resistance, Fungal*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Microbial Sensitivity Tests / standards

Substances

  • Antifungal Agents
  • Amphotericin B